Human VEGF165 Protein, premium grade

GMP version GMP-VE5H23 is now available for seamless transition.
1/12
+9 View all
Cat. No. / Size
Price
Availability
Qty
Premium grade lyophilized
VE5-H4210-20ug
$285.00
In Stock - Delivery in 1-2 business days
VE5-H4210-50ug
$415.00
In Stock - Delivery in 1-2 business days
VE5-H4210-1mg (500ug X 2)
$2,985.00
In Stock - Delivery in 1-2 business days
GMP lyophilized
GMP-VE5H23-50ug
$570.00
In Stock - Delivery in 1-2 business days
GMP-VE5H23-1mg (50ug X 20)
$4,325.00
In Stock - Delivery in 2-3 weeks
GMP-VE5H23-10mg (50ug X 200)
$30,275.00
VE5-H4210
Sub-Total :
$ 0
Customize Product Request Quote
Contact Us
Contact Us
Sub-Total:
$ 0
  • Product Details
  • Performance Data
  • Reviews & Citations
  • Important Statement
  • Resources
Features and Advantages
  • Seamless Transition from Preclinical to Clinical: Same cell clone, process, and QC as GMP products.
  • Enhanced Production Standards: AOF raw materials, pharma-grade excipients, Grade B+A (ISO 5) environment.
  • Comprehensive Quality Control: Additional strict testing for process impurities, sterility, and mycoplasma.
  • Cost-Effective Solution: GMP-comparable quality at an economical price for early development.
  • Risk Mitigation: Enhanced safety through rigorous impurity control and comprehensive testing.
Synonyms

RP1-261G23.1, MGC70609, MVCD1, VEGFA, VPF

Source

Human VEGF165, premium grade (VE5-H4210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4). In the region Ala 27 - Arg 191, the amino acid sequences of VEGF165 from Human, Cynomolgus and Rhesus macaque are identical.

Predicted N-terminus: Ala 27

It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage.
GMP-VE5H23 is the GMP version of this VE5-H4210. These two proteins display indistinguishable performance profiles, thereby ensuring a seamless transition for end users from early preclinical stage to later clinical phases.

Molecular Characterization

This protein carries no "tag".

The protein has a calculated MW of 19.2 kDa. The protein migrates as 24 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 0.01 EU per μg by the LAL method / rFC method.

Host Cell Protein

<0.5 ng/µg of protein tested by ELISA.

Host Cell DNA

<0.02 ng/μg of protein tested by qPCR.

Sterility

Negative

Mycoplasma

Negative

Purity

>95% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 24 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
Quality Description

ACRO's Research-grade products are suitable for a wide range of cell culture applications, particularly for research use in academic institutions. These products are sterilized by filtration, followed by lyophilization where applicable. Typical specifications include endotoxin levels of <0.01 EU/μg and purities >95%. Biological activity is calibrated against WHO/NIBSC standards when available.
ACRO's Premium-grade (Pre-GMP) products are characterized by their high quality and enhanced safety profiles, making them ideal for early-stage discovery and manufacturing processes in cell therapy companies. A key advantage is their seamless transition to corresponding GMP-grade versions. Biological activity is calibrated against WHO/NIBSC standards when available. Typical specifications include endotoxin levels of <0.01 EU/μg and purities >95%. In addition, rigorous testing is conducted to ensure the absence of mycoplasma, HCD, and HCP, thereby guaranteeing product safety.

Background

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.